Atogepant shows efficacy for prevention of migraine
Atogepant, an oral drug approved in the US for the prevention of episodic migraine treatment appears to also be effective for the prevention of chronic migraine. The findings of… read more.
Atogepant, an oral drug approved in the US for the prevention of episodic migraine treatment appears to also be effective for the prevention of chronic migraine. The findings of… read more.
When women suffer migraine attacks, it is often just before or during their monthly period. A team of researchers from Charité – Universitätsmedizin Berlin has now identified a… read more.
Migraine is a major cause of disability, affecting about 12% of people. A 2-part series published in CMAJ (Canadian Medical Association Journal) on diagnosing and managing the condition with both… read more.
Lidocaine infusions appear to offer significant relief to patients with refractory chronic migraine. Researchers reported this finding on May 23, 2022 in the journal Regional Anesthesia & Pain Medicine…. read more.
An international consortium of leading migraine scientists identified more than 120 regions of the genome that are connected to risk of migraine. The groundbreaking study helps researchers better… read more.
The FDA has approved Qulipta (atogepant tablets), from AbbVie, for the preventive treatment of episodic migraine in adults. The approval of Qulipta was based on findings from the… read more.
BioDelivery Sciences International, Inc. a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced that it has completed the acquisition of U.S. and Canadian rights… read more.
Migraines are linked to poorer quality sleep in both adults and children, researchers reported on Sept. 22, 2021 in Neurology As background to the new meta-analysis, investigator and… read more.
This study of 182 adults with frequent migraines expanded on the team’s previous work on the impact of linoleic acid and chronic pain. Linoleic acid is a polyunsaturated… read more.
“Migraine is one of the most common headache disorders, but only about half the people taking medication for it get real relief,” said study author Rohit Bhatia, M.D.,… read more.
The migraine treatment rimegepant also appears to have efficacy in preventing migraines, researchers reported on Dec. 15, 2020 in The Lancet.